Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
Dimitrios A PappasJacqueline O'BrienLin GuoYing ShanJoshua F BakerGregory KricorianScott StrykerDavid H CollierPublished in: Arthritis research & therapy (2023)
This analysis of real-world data from the CorEvitas RA Registry did not show differences in clinical effectiveness and treatment persistence rates in b/tsDMARD-naïve patients initiating ETN, ADA, or JAKi as first-line targeted therapy either alone or in combination with csDMARDs.
Keyphrases
- rheumatoid arthritis
- randomized controlled trial
- newly diagnosed
- ejection fraction
- disease activity
- juvenile idiopathic arthritis
- stem cells
- prognostic factors
- systemic lupus erythematosus
- mesenchymal stem cells
- bone marrow
- rheumatoid arthritis patients
- systemic sclerosis
- cell therapy
- data analysis
- patient reported